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Abstract 35 
 36 
Introduction Knowledge about global use patterns of contraceptive implants is limited. This study 37 
aims to describe implant use patterns from a user and prescriber perspective. 38 
Material and methods In a cross-sectional design, we estimated the annual number of users by 39 
calculating doses sold per 1000 women-years in the Norwegian Prescription Database for the years 40 
2006-2012. For each contraceptive method, we calculated on an annual basis a proportion of defined 41 
daily doses (DDDs) of all hormonal contraceptives in five years age groups. Data were analyzed in 42 
SPSS version 22, with chi-square test, t-test, and survival analysis.  43 
Results Sales from pharmacies for contraceptive implants more than doubled over the study years 44 
and was consistently higher in the younger age groups. The collection rate was 9.3 per 1000 women 45 
in 2012, when implant sales amounted to 2.4% of all daily doses of hormonal contraceptives sold. 46 
General practitioners and doctors with no specialty were the major prescribers to starters of 47 
contraceptive implants, whereas gynecologists prescribed nearly 12% of the volume, a higher 48 
proportion to women > 35 years of age than younger women.  The cumulative proportions of 49 
continued users at 6-, 12-, 24-, and 36-months were 96.1%, 78.6%, 51.9%, and 34.9%, significantly 50 
lower for users who had doctors with no specialty as prescribers. At end of first expiration period, 51 
21% of starters continued using implants. 52 
Conclusion Implants play a minor role in the overall use of hormonal contraception in Norway. One 53 
in five starters continue as long-term users. 54 
 55 
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COCs – Combined oral contraceptives 62 
LNG-IUD -Levonorgestrel-releasing intrauterine device  63 
NorPD- Norwegian prescription database 64 
OCs – Oral contraceptives 65 
POPs – Progestin only pills 66 
VR(s) – vaginal ring(s) 67 
 68 
 69 
Key message 70 
Implants play a minor role in the overall use of hormonal contraception in Norway. It’s use 71 
amounted 2.4% of all hormonal contraception in 2012. Mean duration of use was 27 months (ranging 72 
0-91 months). 73 
 74 
  75 
Introduction  76 
Contraceptive implants have been available publicly since 1983. In the Western world, the popularity 77 
of implants increased in the late 1990s when newer products with one or two rods replaced the six-78 
rod package (Norplant I). Contraceptive implants, which act as progestin-only pills as they contain 79 
slow-releasing gestagens, entered the Norwegian market in 2002. Inserted subdermally, protection 80 
against pregnancy for three (Implanon/Nexplanon (one rod of etonogestrel)) or five years 81 
(Jadelle/Norplant II (two rods of levonorgestrel)) may be achieved. Contraceptive implants are very 82 
efficacious and safe methods of contraception in comparison with pills, vaginal rings, and the 83 
contraceptive patches (1–6). Reported continuation rates in clinical trials vary between 78–92%, 67–84 
83%, and 61–67% at one, two, and three years respectively (1–4). Vaginal bleeding disorders are the 85 
most common reason for discontinuation (1–7).  86 
 Knowledge about implant use patterns worldwide is scarce (8). Norway has reported low user 87 
rates among teenagers (9) and among women in the general population (10). This study aims to 88 
analyze the use pattern of contraceptive implants in Norway in a client and a prescriber perspective. 89 
 90 
Material and methods 91 
The Norwegian Prescription Database (NorPD), which stores information about users and 92 
prescribers, was established January 1, 2004. The NorPD registers drugs delivered from pharmacies 93 
to users. A fictitious number is created from the personal identification number given to all 94 
Norwegians at birth or upon immigration. Through these pseudonyms, prescriptions can be followed 95 
over time for both users and prescribers. For users the NorPD includes information on month and 96 
year of birth, gender, and home municipality. Detailed information about the prescribed drugs is also 97 
registered. Prescriber information comprises gender, year of birth and graduation, profession, and 98 
year and type of specialty.  99 
A total of 9 237 169 hormonal contraceptive (ATC-codes G02B and G03A) prescriptions 100 
were registered in NorPD from January 1, 2004 to June 30, 2013. We excluded contraceptive 101 
prescriptions to men (n=1 723), research-related contraceptive prescriptions (n=643), prescriptions to 102 
non-Norwegian citizens/persons with incomplete identity (n=11 890), and obvious errors in year of 103 
birth (n=4 523). In addition, we excluded prescriptions undertaken by dentists (n=1 065), dental 104 
assistants (N=369), veterinarians (n=74), opticians (N=19), and prescriptions with errors in number 105 
of packages delivered over the counter at pharmacies (n=959). Among 9 215 904 valid prescriptions, 106 
we identified 19 935 first-time implant users from January 1, 2006 to December 31, 2012 as study 107 
participants. After excluding 78 women who lacked information on year of birth and/or gender of 108 
prescriber, the study population comprised 19 857 first-time implant users. 109 
Use duration was estimated in months, from the date of the first collected implant 110 
prescription until the date of expiration of the last continuous implant prescription, or date of 111 
collection of prescription for other hormonal contraceptives, or study end June 30, 2013. The study 112 
includes women who collected other hormonal contraceptive prescriptions at the same time or within 113 
the first 20 days after an implant prescription (N=110; 0.6%), since they had obviously intended to 114 
start using an implant. Use duration for this group was set to zero months.  115 
 “Switchers” started implant use within 28 days from expiration of the last collected 116 
contraceptive, if last contraceptive was oral, vaginal ring, injection, or a patch. A time limit was not 117 
defined where the last hormonal contraceptive was a levonorgestrel releasing-intrauterine device 118 
(LNG-IUD), since we could not know the exact timing of removal before implant initiation. At study 119 
end, women who bought another hormonal contraceptive within 180 days after expiration of last 120 
implant prescription comprised the “switchers.” A “pause” in hormonal contraception use was 121 
restricted to women who submitted an implant prescription 29 days or later after the most recent 122 
collected contraceptive prescription expired. At the study’s end, pause denoted women who collected 123 
another hormonal contraceptive 180 days or later after expiration of the last dispensed implant. 124 
Continuous implant users were women who collected another implant within 180 days after the 125 
expiration of the most recent collection. 126 
 In the overall assessment of hormonal contraceptive consumption, we set the implant use 127 
duration to two years (Implanon/Nexplanon) and four years (Jadelle), and the LNG-IUD 128 
(LevoNova/Mirena) to four years. For other hormonal contraceptives, we estimated the annual 129 
number of users by calculating the daily doses sold per day/1000 women in age groups spanning five 130 
years from 15 to 49 years depending on the number of packages and package size dispensed at each 131 
collection, as indicated in the ATC code. Statistics Norway online provided denominator data (age 132 
by calendar year) (11). 133 
 User age was categorized as 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, and 45–49 years, 134 
whereas prescriber age was categorized as 24–34, 35–44, 45–54, 55–64, and 65–80 years. We 135 
included 58 starters aged 12–14 years in the 15–19 group, and 30 starters aged 50–54 years in the 136 
45–49 group. Prescriber’s profession was categorized as general practitioner, gynecologist, other 137 
specialty, public health nurse, or midwife. We categorized physicians without specialist status in the 138 
NorPD as doctors with no specialty. This category comprised postgraduate students from medical 139 
school doing their internship, physicians in a residency-training program, and medical students who 140 
had a valid license issued in fifth year of medical school. Physicians with more than one specialty 141 
were denoted with the most recent specialty.  142 
 All analyses were done in Statistical Package for Social Sciences (SPSS) version 22.0 with 143 
chi-square tests for categorical variables, t-test for continuous variables, and duration of use 144 
estimated by survival analysis with a significance level p < 0.05.  145 
The board of the NorPD reviewed the protocol and gave permission for use of data. 146 
Studies using anonymously data from nationwide registers are by Norwegian legislation 147 
exempted from institutional regulatory board approvals and written informed consent from 148 




The number of implants collected from pharmacies in Norway more than doubled in each age group. 153 
The total take out from 2006 through 2012 was consistently higher among the younger age groups 154 
(Table 1, upper panel). The take out rate in 2006 was 4.3 per 1000 women of reproductive age (15–155 
49), versus 9.3 in 2012 (Table 1, upper panel). Related to proportions of daily doses of hormonal 156 
contraceptives sold, implant sales amounted to 1.2% in 2006, versus 2.4% in 2012, with a steady 157 
year-by-year increase (Table 1, lower panel). The relative use of implants to all other hormonal 158 
contraceptives was highest among teenagers and decreased significantly by age (Table 1, lower 159 
panel). 160 
 The number of women who started using contraceptive implants increased from 2 252 in 161 
2006 to 4 319 in 2012. There was a significant shift to younger starters at the end of the study as the 162 
proportion of starters less than 25 years of age increased from 44% in the first study year to over 163 
60% in the last study year, whereas the proportion of starters 25 years or older decreased (Table 2). 164 
As the NorPD was established on January 1, 2004, we restricted the analysis of previous use 165 
of hormonal contraception to those who started after January 1, 2010. This restriction gave the 166 
women a wider time period in which they had a chance to collect at least one hormonal contraceptive 167 
prescription before initiating implant use. Most women starting with a contraceptive implant began 168 
after a pause in using hormonal contraception (Table 3). The proportion of women without previous 169 
use of hormonal contraception increased by age. For these women the contraceptive implant was the 170 
first use of any hormonal contraception after January 1, 2004. More young women switched from 171 
OCs to implant, whereas more elderly women may have switched from LNG-IUDs to implants.  172 
There were minor differences across age in the proportion of women switching from POPs to 173 
implants. Only a small proportion of women switched from a patch, vaginal ring, or injectable 174 
contraceptive to an implant.  175 
 Women across all age groups selected their provider independent of provider’s sex (Table 4). 176 
Young doctors with no specialty prescribed nearly 40% of the implants, more often to younger 177 
women. General practitioners were the main implant providers, covering 40% of the teenagers, while 178 
increasing to over 50% in the age groups above 30 years. Other specialists prescribed 4% of the 179 
volume evenly distributed across age groups. Gynecologists prescribed nearly 12% of the total 180 
volume, more often to older than young women (Table 4). Public health nurses/midwives are not 181 
certified to prescribe implants. Thus over the entire study period, only 27 instances implicated these 182 
professions in implant distribution. Female doctors dominated in all professional groups listed in 183 
Table 4 at ages below 50, whereas males dominated among doctors 50 years of age or above (data 184 
not shown). 185 
 Within 180 days after collecting the initial implant, approximately 4% of the users had taken 186 
out another hormonal contraceptive prescription, independent of provider’s profession or user’s age.  187 
The cumulative proportions of continued users at 6-, 12-, 24-, and 36-months were 96.1%, 78.6%, 188 
51.9%, and 34.9% respectively. These rates were significantly lower for users whose prescribing 189 
doctors had no specialty, versus users whose prescribing doctors were general practitioners, 190 
gynecologists, or other specialists. Mean use duration was 27.6 months (range 0–91; 95% CI: 27.3–191 
27.9), versus 24.9 months for users who were prescribed an implant by a doctor with no specialty, 192 
and 29.5 months for users who were prescribed an implant by any other profession (p<0.001). 193 
Analysis of use duration was minimally impacted when excluding the 110 (0.6%) women who had 194 
another prescription for hormonal contraceptive within 20 days after the first implant prescription.  195 
Among users who had taken out an implant prescription before 2010 (n=9 605), 20.8% 196 
continued to use another implant within 180 days after the recommended use time. Within this subset 197 
of women, the mean use duration was 57.7 months (range 41–91). 198 
 Women consult a physician’s office for removing the rod(s). At the same time, most women 199 
seek consultation on contraception and may receive another contraceptive prescription. Within 180 200 
days after the expiration of the first implant, nearly all women had taken out another prescription for 201 
hormonal contraception (Table 5). Most women were still using an implant, increasing from 50% in 202 
the younger to over 75% in the older age groups. Switching to OCs and POPs were more prevalent in 203 
younger women. Fewer women switched to a vaginal ring, patch, or injectable once the first implant 204 
prescription expired. Compared to young women, those 30 years or older were more inclined to 205 
switch to a hormonal IUD once the implant prescription expired (Table 5). 206 
 207 
Discussion 208 
 Despite increasing numbers, less than 1% of women at fertile age (15–49 years) in Norway 209 
were collecting a contraceptive implant prescription in 2012. Use increased in all age groups from 210 
2006 to 2012, with highest use in the 15–19 and 20–24 age groups. Implant use is increasing relative 211 
other hormonal contraceptive methods, amounting to 2.4% of all hormonal contraception in 2012. 212 
Over time, the proportion of starters with implants increased among the younger age groups but 213 
decreased in all age groups above 25 years. 214 
 Reliable, global-scale estimates on use of modern contraception, and implants in particular, 215 
are lacking (8). From the most recent World Contraceptive Patterns, few countries reported on 216 
implants (8). In the most recent contraceptive surveys from England (13), the US (12), and France 217 
(14) implants are not reported separately, but included with long-acting reversible contraceptives 218 
(LARC). The latter studies are based on surveys among women in need of contraception (12, 14), 219 
while the study from England reports contraceptive methods for women in contact with the Sexual 220 
and Reproductive Health Services (13). From what national authorities report to WHO, Norway had 221 
the highest worldwide implant use rate in 2011, followed by Australia, United Kingdom, and Austria 222 
(8).   223 
 The strength of this study is the large dataset based on compulsory electronic reporting from 224 
all pharmacies to the NorPD, and the information about providers.  Furthermore, this study evaluates 225 
the real-life situation of implant use patterns over time. A limitation is that we do not know whether 226 
the contraceptive methods collected at the pharmacies are actually used. However, repeated 227 
prescriptions do suggest that the contraceptives are used, where nearly 100% of the women who had 228 
reached the first implant’s expiration time obtained another prescription for hormonal contraception.  229 
 In Norway, all citizens have a right to choose a general practitioner from a list of authorized 230 
physicians (16). Over the study years, 99% of the target population of women at reproductive age 231 
had a primary care physician (16). Contraceptive counselling is considered a task for general 232 
practice, thus explaining why general practitioners were the main providers of implants at any age. 233 
Gynecologists contribute to contraceptive counselling, but far less than general practitioners and 234 
doctors with no specialty. 235 
 Doctors with no specialty are at the start of their career and may meet women who seek 236 
contraception on irregular basis without a permanent professional relationship. Factors related to the 237 
situation in which contraceptive counselling takes place, the premature contraceptive counselling 238 
experience among this subgroup of physicians, or factors related to the women who seek doctors 239 
with no specialty, may explain why users of this subset of physicians had a significantly shorter use 240 
duration.  241 
 Women participating in clinical trials on hormonal contraception are often recruited from 242 
patient lists in health management systems of general practitioners, gynecologists, or health facilities 243 
that offer a wider range of service. Most eligible women in these settings will be previous or current 244 
contraception users. Clinicians may invite healthy, previous users to clinical trials based on 245 
established information in their medical information systems. The cumulative proportion of implant 246 
users reported in this study is in the lower range of what is reported from clinical trials after one 247 
year, but lower than what is reported after two and three years (1–4). Women in clinical trials of 248 
long-acting contraceptive methods may be more motivated for long-term use than women being 249 
advised the method on general terms. In addition, participation in clinical trial includes regular but 250 
shorter follow-up windows, better overall care, and investigators that may have an interest in keeping 251 
the women in the studies.  252 
The present estimates on continuation rates, expressed as cumulative proportions, may be 253 
overestimated as the rods may have been removed before the next prescription for a hormonal 254 
contraceptive is collected, despite the fact that subsequent prescription were collected within the 255 
implant’s expiration window.  256 
 When comparing results from clinical trials to registry-based studies, there are inborn pitfalls 257 
that hamper comparisons. The recruitment setting may explain why more starter women in clinical 258 
trials switched from OCs to implants (23–27%) compared to our study (16%), whereas there were 259 
less differences in non-users prior start (3, 7). At study end more starters continued implant use in 260 
our study, while more women switched to OCs in another study (7). There are limited data in the 261 
literature on switching and pauses in hormonal contraceptive use. 262 
 Women in Norway pay for implants. Assuming that an average implant user continues for at 263 
least 30 months, the monthly price for implants is similar to the cost for the cheapest OCs. The only 264 
levonorgestrel-containing implant (Jadelle) was withdrawn from the market in 2011, while the 265 
etonogestrel-releasing implant “Implanon” was replaced by a new insertion package and a new brand 266 
name, “Nexplanon,” in 2010. We do not consider the media attention and “Nexplanon” campaigning 267 
as important for the increase in overall implant use, as there was a steady increase in implants from 268 
the first to the last study year. During the entire study period the Norwegian government has 269 
encouraged greater LARC use, including implants, especially in the younger age groups, in order to 270 
make women more conscious of reaching their own reproductive goals (17, 18). An increased LARC 271 
uptake, may generate cost savings for both the health care system and the contraceptive user by 272 
better contraceptive adherence, and lead to a decrease in unplanned pregnancies (19).  273 
  In summary, implants play a minor role in the overall use of hormonal contraception 274 
in Norway. Implant use is increasing, especially among young women under 25 years of age. Main 275 
implant prescribers are general practitioners and doctors with no specialty status. The cumulative 276 
proportions of continuing implant users at one, two, and three years are lower than reported from 277 
clinical trials. One out of five starters renewed the prescription at expiration time and continued as 278 
long-term users.   279 
 280 
 281 
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Table 1: Estimated proportion of contraceptive implant users per 1 000 women in the general 
population (upper panel) and per 1 000 women using hormonal contraception (lower panel), by age 
and calendar year. Norway 2006 through 2012 (‰). 
Year/ 
Age 
2006 2007 2008 2009 2010 2011 2012 
‰ ‰ ‰ ‰ ‰ ‰ ‰ 
15–19 6 8 8 9 7 11 15 
20–24 9 12 13 14 12 18 23 
25–29 6 7 7 8 6 9 11 
30–34 5 5 5 6 5 6 7 
35–39 4 4 3 4 3 4 5 
40–44 2 2 2 3 2 3 3 
45–49 0.4 0.6 1 1 1 1 2 
Total 4 5 5 6 5 7 9 
Year/ 
Age 
       
15–19 14 19 20 22 19 26 36 
20–24 14 16 18 20 16 23 30 
25–29 11 13 13 15 12 17 22 
30–34 12 13 12 16 12 17 19 
35–39 12 13 11 12 10 14 18 
40–44 09 09 11 11 09 11 13 
45–49 04 06 09 08 07 09 12 
Total 12 14 15 16 13 19 24 
 
  
Table 2: Age distribution among implant starters, by age and calendar year.                                     
Norway 2006 through 2012 (%). 
Year/ 
Age 
2006 2007 2008 2009 2010 2011 2012 
N=2252 N=2558 N=2442 N=2353 N=2679 N=3254 N=4319 
% % % % % % % 
15–19 17.2 21.6 23.6 24.2 24.6 25.1 26.0 
20–24 27.0 28.5 29.2 32.3 31.6 34.6 35.3 
25–29 17.3 18.0 18.1 16.4 16.8 15.9 15.8 
30–34 16.7 14.1 13.0 11.9 12.5 11.9 10.5 
35–39 13.8 11.3 9.6 8.5 8.3 7.3 7.1 
40–44 6.3 5.0 5.2 4.9 4.4 3.8 4.0 
45–49 1.6 1.6 1.4 1.7 1.7 1.4 1.5 






Table 3: Switching contraceptive method prior starting a contraceptive implant, by age and total. 
Norway 2010 through 2012 (%). 
Age/ 
Method used 
15–19 20–24 25–29 30–34 35–39 40–44 45–49 Total 
N=2598 N=3496 N=1650 N=1175 N=767 N=412 N=154 N=10252 
% % % % % % % % 
Pause 30.3 45.9 53.6 54.4 49.2 40.0 28.6 43.9 
1st registr. 15.0 8.3 14.8 13.0 20.2 21.8 38.3 13.5 
OCs 29.0 19.9 7.6 5.4 4.2 5.3 3.9 16.6 
Vaginal ring 2.5 3.4 2.0 1.4 0.4 0.7 0.6 2.3 
Patch 2.8 2.2 1.5 1.0 1.7 1.0 0.0 2.0 
POPs 16.5 16.2 13.9 14.5 10.6 13.3 9.7 15.1 
Injectable 3.5 2.9 2.9 3.0 5.2 5.6 4.5 3.4 
LNG-IUD 0.4 1.2 3.7 7.3 8.6 12.1 14.3 3.3 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
1st registr. = 1st registration in the Norwegian Prescription Database. OCs = oral contraceptives. POPs 








15–19 20–24 25–29 30–34 35–39 40–44 45–49 Total 
N=4 684 N=6 305 N=3 328 N=2 510 N=1 801 N=923 N=306 N=19857 
% % % % % % % % 
Sex         
Male 48.5 50.4 51.1 50.2 51.2 52.8 50.7 50.2 
Female 51.5 49.6 48.9 49.8 48.8 47.2 49.3 49.8 
         
Profession         
MDs no specialty  43.7 42.4 37.1 32.8 28.0 24.6 22.5 38.1 
Gen. practitioners 41.6 42.3 46.1 51.8 55.1 54.0 57.2 45.9 
Other specialists 4.1 4.3 4.3 4.5 3.7 4.8 3.6 4.2 
Gynecologists 10.2 10.9 12.5 10.9 13.2 16.7 16.7 11.6 
Pub. health nurses 0.4 0.1      0.1 






Table 5: Switching contraceptive method within 180 days after expiration of a contraceptive implant 




15–19 20–24 25–29 30–34 35–39 40–44 45–49 Total 
N=4 684 N=6 305 N=3 328 N=2 510 N=1 801 N=923 N=306 N=19 857 
% % % % % % % % 
Pause 0.5 0.5 0.5 0.5 0.6 0.7 0.3 0.5 
OCs 30.7 26.6 20.6 15.6 10.0 5.7 1.6 22.3 
Patch 4.4 5.1 4.6 2.6 2.9 0.8 1.0 4.1 
Vaginal ring 3.5 2.8 2.9 2.2 1.7 0.7 0.0 2.7 
POPs 9.5 10.5 11.3 8.3 6.7 5.5 4.2 9.5 
Injectable 2.9 2.4 2.7 2.9 4.2 4.8 2.6 2.9 
Implant 47.7 50.2 53.9 61.4 66.4 74.6 86.9 54.8 
LNG-IUD 0.9 1.9 3.6 6.6 7.6 7.3 3.3 3.3 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
OCs = oral contraceptives. POPs = progestin-only pills. LNG-IUD = levonorgestrel intrauterine device. 
 
 
